en · de · es · fr · pt
thymosin-alpha-1-notes.peptides9002.com › Info › Research History And Clinical Assessment — Complete Guide

Research History And Clinical Assessment — Complete Guide

By Editorial Desk · published 2026-02-17 · last reviewed 2026-03-26 · Info

This is a working overview of freeze-thaw, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-03-26. Anything still debated is marked as such rather than presented as settled.

Research History and Clinical Assessment

Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.

Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.

Handling, Storage, and Analysis

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.

Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.

Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.

Thymosin-alpha-1 at a glance

PropertyValueNotes
First described1977Reported as a component of thymosin fraction 5
Sequence length28 amino acidsN-terminal residue is acetylated
Net charge at neutral pHNegativeReflects a high proportion of acidic residues
Principal studied usesChronic hepatitis B and vaccine adjuvantResearch uses outnumber approved indications
Regulatory statusApproved in a limited number of countriesNot approved in the United States or most of Europe

Molecular Identity Of Thymosin Alpha-1

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.

Related pages on this site

Identity and Molecular Background

Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.

The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.

Further detail

== In biochemistry == Many biologically active molecules are chiral, including the naturally occurring amino acids (the building blocks of proteins) and sugars. The origin of this homochirality in biology is the subject of much debate. Most scientists believe that Earth life's "choice" of chirality was purely random, and that if carbon-based life forms exist elsewhere in the universe, their chemistry could theoretically have opposite chirality. However, there is some suggestion that early amino acids could have formed in comet dust. In this case, circularly polarised radiation (which makes up 17% of stellar radiation) could have caused the selective destruction of one chirality of amino acids, leading to a selection bias which ultimately resulted in all life on Earth being homochiral. Enzymes, which are chiral, often distinguish between the two enantiomers of a chiral substrate. One could imagine an enzyme as having a glove-like cavity that binds a substrate. If this glove is right-handed, then one enantiomer will fit inside and be bound, whereas the other enantiomer will have a poor fit and is unlikely to bind. L-forms of amino acids tend to be tasteless, whereas D-forms tend to taste sweet. Spearmint leaves contain the L-enantiomer of the chemical carvone or R-(−)-carvone and caraway seeds contain the D-enantiomer or S-(+)-carvone. The two smell different to most people because our olfactory receptors are chiral.

Gallium nitrate is used to treat the side effects of cancer; gallium citrate, a radiopharmaceutical, facilitates imaging of inflamed body areas. Selenium sulfide is used in medicinal shampoos and to treat skin infections such as tinea versicolor. Iodine is used as a disinfectant in various forms. Bismuth is an ingredient in some antibacterials.

Fungal infections; Pneumocystis jiroveci, histoplasmosis, coccidioidomycosis, paracoccidioidomycosis, candidiasis Other granulomatous conditions; PR3+ vasculitis, Crohn's disease, acute granulomatous pneumonia, talc granuloma, silicone-induced granuloma, BCG-associated, granulomatous hepatitis, paraffin-associated granuloma Genetic conditions; Williams syndrome, pseudoxanthoma elasticum, CYP24A1 mutation (adult / infantile), SLC34A1 mutation Miscellaneous; mycobacterium avium, leprosy, lipoid pneumonia, cat scratch fever, berylliosis Some plants contain glycosides of 1,25-dihydroxycholecalciferol. Consumption of these glycosides by grazing animals leads to vitamin D toxicity, resulting in calcinosis, the deposition of excessive calcium in soft tissues. Three rangeland plants, Cestrum diurnum, Solanum malacoxylon, and Trisetum flavescens, are known to contain these glycosides. Of these, only C. diurnum is found in the U.S., mainly in Florida.

Dental treatment (e.g. dentoalveolar surgery/procedure that impacts bone) – it is possible for MRONJ to occur spontaneously without any recent invasive dental treatment Duration of bisphosphonate drug therapy – increased risk with increased cumulative dose of drug Other concurrent medication – use of chronic systemic glucocorticoid increases risk when they are taken in combination with anti-resorptive drugs Dental implants Drug holidays – no evidence to support a reduction in MRONJ risk if patients stop taking bisphosphonates temporarily/permanently, as drugs can persist in skeletal tissues for many years Treatment in the past with anti-resorptive/anti-angiogenic drugs Patient being treated for cancer – higher risk Patients being treated for osteoporosis/non-malignant bone diseases (e.g. Paget's disease) – lower risk

Sources: en.wikipedia.org

Background from the literature

== Further reading == Almond, Mark (2002). Uprising!: Ideological Shifts and Political Upheavals That Have Shaped the World. London: Octopus Publishing Group. ISBN 978-0-7607-3348-6. Garton Ash, Timothy (1990). The magic lantern: the revolution of '89 witnessed in Warsaw, Budapest, Berlin, and Prague. New York: Random House. ISBN 978-0-394-58884-1. Deletant, Dennis (1999). Romania under communist rule. Iasi: The Center for Romanian Studies. ISBN 978-973-98392-8-0. Gives a detailed account of the events in December 1989 in Timișoara. Engel, Jeffrey A. (2017). When the world seemed new: George H.W. Bush and the end of the Cold War. Boston; New York: Houghton Mifflin Harcourt. ISBN 978-0-547-42306-7. Ștefănescu, Domnița (1995). Cinci ani din istoria Romaniei: o cronologie a evenimentelor (decembrie 1989-decembrie 1994) [Five years of Romanian history: a chronology of events (December 1989-December 1994)] (in Romanian). Bucharest: Mașina de Scris. ISBN 978-9-73-971622-2. OCLC 909545436.

Glucose and oxygen supply almost all the energy for the brain, so its availability influences psychological processes. When glucose is low, psychological processes requiring mental effort (e.g., self-control, effortful decision-making) are impaired. In the brain, which is dependent on glucose and oxygen as the major source of energy, the glucose concentration is usually 4 to 6 mM (5 mM equals 90 mg/dL), but decreases to 2 to 3 mM when fasting. Confusion occurs below 1 mM and coma at lower levels. The glucose in the blood is called blood sugar. Blood sugar levels are regulated by glucose-binding nerve cells in the hypothalamus. In addition, glucose in the brain binds to glucose receptors of the reward system in the nucleus accumbens. The binding of glucose to the sweet receptor on the tongue induces a release of various hormones of energy metabolism, either through glucose or through other sugars, leading to an increased cellular uptake and lower blood sugar levels. Artificial sweeteners do not lower blood sugar levels. The blood sugar content of a healthy person in the short-time fasting state, e.g. after overnight fasting, is about 70 to 100 mg/dL of blood (4 to 5.5 mM). In blood plasma, the measured values are about 10–15% higher. In addition, the values in the arterial blood are higher than the concentrations in the venous blood since glucose is absorbed into the tissue during the passage of the capillary bed. Also in the capillary blood, which is often used for blood sugar determination, the values are sometimes higher than in the venous blood.

== Interactions == Itraconazole and fluvoxamine slow down the rate of elimination of etizolam, leading to accumulation of etizolam, therefore increasing its pharmacological effects. Carbamazepine speeds up the metabolism of etizolam, resulting in reduced pharmacological effects.

biosynthesis from the sulfur amino acids (e.g., cysteine); active uptake by a taurine transporter; and the extent of its release from cells by a "volume-sensitive leak pathway". Taurine is a major constituent of bile, and can be found in the large intestine. Its concentrations in land plants are low or undetectable, but up to a substantial wet weight has been found in algae.

== Bioanalytical organisations == There are several national and international bioanalytical organisations active throughout the world. Often they are part of a bigger organisation, e.g. Bioanalytical Focus Group and Ligand Binding Assay Bioanalytical Focus Group, which are both within the American Association of Pharmaceutical Scientists (AAPS) and FABIAN, a working group of the Analytical Chemistry Section of the Royal Netherlands Chemical Society. The European Bioanalysis Forum (EBF), on the other hand, is independent of any larger society or association.

Sources: en.wikipedia.org

Further detail

The three-member tribunal was unanimous in its decision. The tribunal repeated prior criticisms of the governance of the Essendon's supplements program, which had been seen in the ASADA interim report and the Switkowski report. As a result of the verdict, the provisional suspensions on the players were lifted, and all affected players were eligible to play in Round 1. ASADA and the AFL were given a window of 21 days to appeal the decision. The verdict was handed down in private, and few other details about the reasons for the decision were released.

=== Sources === For the most part, vitamins are obtained from the diet, but some are acquired by other means: for example, microorganisms in the gut flora produce vitamin K and biotin; and one form of vitamin D is synthesized in skin cells when they are exposed to a certain wavelength of ultraviolet light present in sunlight. Humans can produce some vitamins from precursors they consume: for example, vitamin A is synthesized from beta carotene; and niacin is synthesized from the amino acid tryptophan. Vitamin C can be synthesized by some species but not by others. Vitamin B12 is the only vitamin or nutrient not available from plant sources. The Food Fortification Initiative lists countries which have mandatory fortification programs for vitamins folic acid, niacin, vitamin A and vitamins B1, B2 and B12.

Jungermann K, Thauer RK, Leimenstoll G, Decker K (1973). "Function of reduced pyridine nucleotide-ferredoxin oxidoreductases in saccharolytic Clostridia". Biochim. Biophys. Acta. 305 (2): 268–80. doi:10.1016/0005-2728(73)90175-8. PMID 4147457.

=== Transamination === Urea undergoes transamination. For example, treatment with anilinium gives both N-phenylurea and N,N'-diphenylurea. N-Methylurea can be prepared by a similar acid-catalyzed pathway.

Sources: en.wikipedia.org

Frequently asked questions

Why are clinical results inconsistent?

Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.

In which countries is thymosin alpha 1 approved?

Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.

How is the peptide characterized in review articles?

Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.

How should the dry powder be stored?

Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.

Network